Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial.

Amorosa VK, Luetkemeyer A, Kang M, Johnson VA, Umbleja T, Haas DW, Yesmin S, Bardin MC, Chung RT, Alston-Smith B, Tebas P, Peters MG
HIV Clin Trials. 2013 14 (6): 274-83

PMID: 24334180 · PMCID: PMC4113390 · DOI:10.1310/hct1406-274

MeSH Terms (18)

Adult Animals Antiviral Agents Drug Therapy, Combination Female Hepacivirus Hepatitis C HIV-1 HIV Infections Humans Interferon-alpha Male Middle Aged Pilot Projects Polyethylene Glycols Recombinant Proteins Ribavirin Thiazoles

Connections (1)

This publication is referenced by other Labnodes entities: